Highlights Marinus Pharmaceuticals, Inc. London S.E.

Equities

0JYL

US56854Q2003

Market Closed - London S.E. Other stock markets 09:50:38 2021-02-04 am EST			After market 11:59:31 am
13.97 ^USD	-0.43%		1.365	-90.23%

Jul. 01	Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 3000E Growth Index	CI
Jul. 01	Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2000 Growth Index	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sector Update: Health Care Stocks Decline Premarket Monday	Jun. 17	MT
Top Premarket Decliners	Jun. 17	MT
Marinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study	Jun. 17	MT
Marinus Pharmaceuticals Announces Topline Results from Phase 3 Rise Trial of IV Ganaxolone in Refractory Status Epilepticus	Jun. 17	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	May. 17	MT
Sector Update: Health Care	May. 17	MT
Marinus Completes Enrollment in Tuberous Sclerosis Complex Trial; Gets New Patent	May. 17	MT
Marinus Pharmaceuticals, Inc. Announces Key Business Updates for Tuberous Sclerosis Complex Program	May. 17	CI
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M	May. 08	MT
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024	May. 08	CI
Sector Update: Health Care Stocks Softer Late Afternoon	Apr. 15	MT
Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial	Apr. 15	CI
Marinus Pharmaceuticals Q4 Net Loss Wider Than Expected While Revenue Misses Forecast; Shares Drop Premarket	Mar. 06	MT
Marinus Pharmaceuticals Q4 Net Loss Narrows, Revenue Higher; Shares Plunge After-Hours	Mar. 05	MT
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Posts Q4 Revenue $7.2M, vs. Street Est of $8.1M	Mar. 05	MT
Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024	Mar. 05	CI
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 05	CI
Marinus Pharmaceuticals Raises 2023 Product Revenue Expectation	Jan. 04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Marinus Pharmaceuticals, Inc. London S.E.

Equities

0JYL

US56854Q2003

Highlights

Filters